Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Abbott and Alere Amend Merger Agreement
Davis Polk is advising J.P. Morgan as financial adviser to Alere Inc. in connection with the amendment of the existing terms…
Evolent Health Common Stock Secondary Offering
Davis Polk advised the underwriters in connection with a secondary offering of 7,500,000 shares of Class A common stock of…
Abbott Laboratories $2.9 Billion Exchange Offers and Consent Solicitations
Davis Polk advised the joint lead dealer managers in connection with the registered offers by Abbott Laboratories to…
Davis Polk Advises Penumbra, Inc. on Its Follow-On Offering
Davis Polk advised Penumbra, Inc. on its SEC-registered follow-on public offering of 1,495,000 shares of common stock for an…
Editas Medicine, Inc. $90 Million Follow-On Offering
Davis Polk advised the active joint book-running managers and representatives of the underwriters in connection with the $90…
Davis Polk Advises Valeant Pharmaceuticals International, Inc. on Its $6.25 Billion Refinancing
Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to…
Bristol-Myers Squibb Company $1.5 Billion Notes Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters on an SEC-registered public…
Davis Polk Advises Auris Medical Holding AG on Its Offering of Common Shares and Warrants to Purchase Common Shares
Davis Polk advised Auris Medical Holding AG on its $10 million public offering of 10,000,000 of its common shares and 10,000…
Hermes Pardini R$763 Million Initial Public Offering
Davis Polk advised the joint bookrunners in connection with the initial public offering by Hermes Pardini and the selling…
Coherus BioSciences, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of…